GSK's 3Q Results Are a Mixed Bag -- Market Talk

Dow Jones10-30

1504 GMT - GSK's 3Q performance was mixed, with a profit beat but weakened vaccines sales, Barclays analysts say in a note. The British pharma giant delivered expectations at the group level but missed sales estimates for its key vaccine shots that led the company to lower its annual vaccine segment outlook, they say. Investors' focus will be on the sales outlook for the next two years for its RSV vaccine Arexvy and its best-selling shingles vaccine Shingrix, Barclays says. Shares fall 3.6% to 14 pounds. (helena.smolak@wsj.com)

 

(END) Dow Jones Newswires

October 30, 2024 11:04 ET (15:04 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment